

- key marker of functional regulatory T cells. *J Immunol Res* 2015; 2015:171520.
58. Miska J, Rashidi A, Chang AL, Muroski ME, Han Y, Zhang L, et al. Anti-GITR therapy promotes immunity against malignant glioma in a murine model. *Cancer Immunol Immunother* 2016;65:1555–67.
 59. Tai X, Van Laethem F, Pobezinsky L, Guintier T, Sharrow SO, Adams A, et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. *Blood* 2012;119:5155–63.
 60. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. *Cancer Immunol Res* 2013;1:32–42.
 61. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong L-Y, et al. The incidence, correlation with tumor infiltrating inflammation, and prognosis of p-STAT3 expression in human gliomas. *Clin Cancer Res* 2008;14:8228–35.
 62. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 2009;9:798–809.
 63. Piao Y, Henry V, Tiao N, Park SY, Martinez-Ledesma J, Dong JW, et al. Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. *Oncotarget* 2017;8: 96970–83.
 64. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. *Cancer Res* 2007;67:9630–6.
 65. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimerberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. *Neuro Oncol* 2006;8: 261–79.
 66. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. *Nat Med* 2005;11: 1314–21.
 67. Kryczek I, Wei S, Zou L, Altuwajri S, Szeliga W, Kolls J, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. *J Immunol* 2007;178:6730–3.
 68. Wei J, Wang F, Kong LY, Xu S, Doucette T, Ferguson SD, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. *Cancer Res* 2013;73:3913–26.
 69. Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, et al. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. *Immunol Lett* 2017; 190:20–5.
 70. Hussain SF, Kong L-Y, Jordan J, Conrad C, Madden T, Fokt I, et al. A Novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. *Cancer Res* 2007;67:9630.
 71. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. Tryptophan catabolism generates autoimmunity-preventive regulatory T cells. *Transl Immunol* 2006;17:58–60.
 72. Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. *Neurosurgery* 2013;72: 1031–8.
 73. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. *Clin Cancer Res* 2012;18:6110–21.
 74. Zhai L, Ladomersky E, Dostal CR, Lauing KL, Swoap K, Billingham LK, et al. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma. *Brain Behav Immun* 2017;62:24–9.
 75. Hanihara M, Kawataki T, Oh-Oka K, Mitsuka K, Nakao A, Kinouchi H. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model. *J Neurosurg* 2016;124: 1594–601.
 76. Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. *Clin Cancer Res* 2014;20:5290–301.
 77. Pirquet V. Das Verhalten der kutanen Tuberkulin-reaktion während der Masern. *Munch Med Wochenschr* 1908;34:1297–300.
 78. Brooks WH, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. *J Exp Med* 1972; 136:1631–47.
 79. Schwartz RH, Mueller DL, Jenkins MK, Quill H. T-cell clonal anergy. *Cold Spring Harb Symp Quant Biol* 1989;54:605–10.
 80. Chiodetti L, Choi S, Barber DL, Schwartz RH. Adaptive tolerance and clonal anergy are distinct biochemical states. *J Immunol* 2006;176: 2279–91.
 81. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. *Int Immunol* 1992;4:661–71.
 82. Fathman CG, Lineberry NB. Molecular mechanisms of CD4+ T-cell anergy. *Nat Rev Immunol* 2007;7:599–609.
 83. Elliott LH, Brooks WH, Roszman TL. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors. *J Immunol* 1984;132:1208–15.
 84. Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. *J Exp Med* 2012;209:1201–17.
 85. Martinez GJ, Pereira RM, Aijo T, Kim EY, Marangoni F, Pipkin ME, et al. The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells. *Immunity* 2015;42:265–78.
 86. Abe BT, Shin DS, Mocholi E, Macian F. NFAT1 supports tumor-induced anergy of CD4(+) T cells. *Cancer Res* 2012;72:4642–51.
 87. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. *J Virol* 2003; 77:4911–27.
 88. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. *Nat Med* 1999;5:677–85.
 89. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. *Immunity* 2007;27:670–84.
 90. Buggert M, Tauriainen J, Yamamoto T, Frederiksen J, Ivarsson MA, Michaelsson J, et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. *PLoS Pathog* 2014;10:e1004251.
 91. Bengsch B, Wherry EJ. The importance of cooperation: partnerless NFAT induces T cell exhaustion. *Immunity* 2015;42:203–5.
 92. Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, et al. CD39 expression identifies terminally exhausted CD8+ T cells. *PLoS Pathog* 2015;11:e1005177.
 93. Liu Z, Han H, He X, Li S, Wu C, Yu C, et al. Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. *Oncol Lett* 2016;11:1829–34.
 94. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J Exp Med* 2010;207:2187–94.
 95. Woroniecka K, Chongsathidkiet P, Rhodin KE, Kemeny HR, DeChant CA, Farber SH, et al. T cell exhaustion signatures vary with tumor type and are severe in glioblastoma. *Clin Cancer Res* 2018 Feb 7 [Epub ahead of print].
 96. Li J, Liu X, Duan Y, Liu Y, Wang H, Lian S, et al. Combined Blockade of T cell immunoglobulin and mucin domain 3 and carcinoembryonic antigen-related cell adhesion molecule 1 results in durable therapeutic efficacy in mice with intracranial gliomas. *Med Sci Monit* 2017;23: 3593–602.
 97. Kim JE, Patel MA, Mangraviti A, Kim ES, Theodoros D, Velarde E, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. *Clin Cancer Res* 2017;23: 124–36.
 98. Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. *Immunogenetics* 1994;39:213–7.

Woroniecka et al.

99. Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. *Eur J Immunol* 1994;24:3216–21.
100. Camisaschi C, Casati C, Rini F, Perego M, De Filippo A, Triebel F, et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. *J Immunol* 2010;184:6545–51.
101. Davis DM. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. *Nat Rev Immunol* 2007;7:238–43.
102. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3 — potential mechanisms of action. *Nat Rev Immunol* 2014;15:45.
103. Joller N, Hafler JP, Brynedal B, Kassam N, Spoerl S, Levin SD, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. *J Immunol* 2011;186:1338–42.
104. Mostafa H, Pala A, Högel J, Hlavac M, Dietrich E, Westhoff MA, et al. Immune phenotypes predict survival in patients with glioblastoma multiforme. *J Hematol Oncol* 2016;9:77.
105. Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. *Immunol Rev* 2017;276:121–44.
106. Guo H, Nan Y, Zhen Y, Zhang Y, Guo L, Yu K, et al. miRNA-451 inhibits glioma cell proliferation and invasion by downregulating glucose transporter 1. *Tumor Biol* 2016;37:13751–61.
107. Macintyre Andrew N, Gerriets Valerie A, Nichols Amanda G, Michalek Ryan D, Rudolph Michael C, Deoliveira D, et al. The glucose transporter glut1 is selectively essential for CD4 T cell activation and effector function. *Cell Metabolism* 2014;20:61–72.
108. Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. *Nat Commun* 2015;6:6692.
109. Chang C-H, Qiu J, O'Sullivan D, Buck Michael D, Noguchi T, Curtis Jonathan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. *Cell* 2015;162:1229–41.
110. Murphy JB, Sturm E. Conditions determining the transplantability of tissues in the brain. *J Exp Med* 1923;38:183–97.
111. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. *Nature* 2015;523:337–41.
112. Laman JD, Weller RO. Drainage of cells and soluble antigen from the CNS to regional lymph nodes. *J Neuro Pharmacol* 2013;8:840–56.
113. Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? *Neuro Oncol* 2011;13:3–13.
114. Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. *Lab Invest* 2017;97:498–518.
115. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. *Clin Cancer Res* 2011;17:4296–308.
116. Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. S1P1 loss mediates T-cell sequestration in bone marrow amidst glioblastoma. *Nat Med*. In press.

Clinical Cancer Research

T-cell Dysfunction in Glioblastoma: Applying a New Framework

Karolina I. Woroniecka, Kristen E. Rhodin, Pakawat Chongsathidkiet, et al.

Clin Cancer Res 2018;24:3792-3802. Published OnlineFirst March 28, 2018.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-18-0047](https://doi.org/10.1158/1078-0432.CCR-18-0047)

Cited articles This article cites 113 articles, 37 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/24/16/3792.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/24/16/3792>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.